Menu
No results found.
Weekly Share Price & Valuation Overview
HUTCHMED
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- HKD 22.08B
- Enterprise Value Operating value: market cap + total debt − cash.
- HKD 20.83B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- HKD 602.20M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- HKD 53.76M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- HKD -7.49M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- HKD 0.70
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 4.16
- Shares Outstanding
- 859.30M
- Float Shares
- 509.01M
- Implied Shares Outstanding
- 939.57M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-1.26%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-1.24%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
8.93%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
77.53%
- ROA Return on assets: net income ÷ total assets.
-
-0.81%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
46.90%
- Revenue Growth Year-over-year revenue growth.
-
-9.20%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
16.33%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
16.63%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 4.47
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.08
- Total Cash Cash and equivalents.
- HKD 1.37B
- Total Debt Short + long-term interest-bearing debt.
- HKD 100.73M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- HKD -1.26B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -13.45
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- HKD -32.56M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- HKD -22.78M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-5.41%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-3.78%
- Cash Conversion (OpCF/EBITDA)
- 4.35
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.